RCS - Theracryf PLC - Potential of Preclinical Program in Mental Fatigue

TheracryfAnnouncement

18/12/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251218:nRSR0206Ma&default-theme=true

RNS Number : 0206M  Theracryf PLC  18 December 2025

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

 

TheraCryf Highlights Potential of Second Preclinical Programme

Targeting Mental and Cognitive Fatigue

·    Chronic fatigue treatment market worth US$1.2 billion in 2024, rising
to c.US$2.3bn by 2033(1)

·    Recent Nature article indicates extent of mental fatigue problem(2)

·    Low levels of dopamine in the brain are linked to mental and
cognitive fatigue

·    TheraCryf's dopamine modulator (DAT) offers a potential treatment for
chronic fatigue

·    Asset at late preclinical stage with published data demonstrating
effectiveness at alleviating fatigue in established models

Alderley Park, 18 December 2025 - TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on brain disorders, notes a recent
Nature article(2) which discusses the extent of the issue of mental fatigue
and highlights the commercial opportunity provided by its second pre-clinical
programme, DAT, which has the potential to treat fatigue.

Central nervous system fatigue is associated with diseases such as multiple
sclerosis (MS), myalgic encephalomyelitis (ME), long COVID and chemotherapy
treatment. More than 80% of patients with multiple sclerosis suffer from
fatigue and report it as the most common and debilitating symptom(3). This
overwhelming cognitive exhaustion, which is not simply being 'tired', severely
impacts daily life. Currently there are no approved treatments for fatigue in
these patients.

The potential market opportunity for treating chronic fatigue was estimated at
US$1.2 billion in 2024 with the market expected to reach US$2.3 billion by
2033(1).

Growing scientific interest in the origins of mental fatigue is underscored by
the recent Nature article(2) by Lynne Peeples which highlights the research
being undertaken to discover the roots of mental fatigue which could point to
treatments for these debilitating disorders. Dopamine plays a major role in
alertness and motivation with low levels being linked to fatigue states(4).

Current treatments include stimulants, such as amphetamines, which produce a
rapid rise in dopamine, however, they are associated with significant side
effects and a high potential for abuse because of the 'rush'-like feelings
they produce.

TheraCryf's DAT asset is differentiated by its ability to gradually increase
levels of brain dopamine without the 'rush'-like profile, potentially
providing a treatment that alleviates mental fatigue without abuse liability.
 

Elevating dopamine levels can also lead to increased wakefulness and the DAT
asset has demonstrated positive preclinical proof of concept in connection
with this, in  models of drug-induced fatigue, MS fatigue and narcolepsy. The
narcolepsy treatment market alone was valued at US$3.48 billion in 2024 and
is expected to reach US$7.73 billion by 2032(5).

Dr Huw Jones, CEO of TheraCryf commented:

"Disease and treatment-related fatigue is a very serious issue for patients
who are already severely affected by several underlying conditions. A
therapeutic that could target these symptoms is clearly needed and the
increase in research efforts and the associated market value related to
fatigue make this a very attractive path to pursue.

"Our dopamine modulator is differentiated and highly selective, with strong
potential in the large and growing area of central nervous system fatigue.
While we progress our lead Ox-1 orexin blocker programme, we continue to
explore the significant potential of the DAT programme for future development
or licensing."

-Ends-

1.     Market Size and Trends: Chronic Fatigue Treatment Market:
https://www.marketsizeandtrends.com/report/chronic-fatigue-syndrome-treatment-market/
(https://www.marketsizeandtrends.com/report/chronic-fatigue-syndrome-treatment-market/)

2.     Is your brain tired? Researchers are discovering the roots of
mental fatigue, Nature 10 December 2025
[https://www.nature.com/articles/d41586-025-03974-w
(https://www.nature.com/articles/d41586-025-03974-w) ]

3.     Dobryakova: Dopamine Imbalance Hypothesis:
https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2015.00052/full
(https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2015.00052/full)

4.     Neural and computational mechanisms of momentary fatigue and
persistence in effort-based choice
(https://www.researchgate.net/publication/353515533_Neural_and_computational_mechanisms_of_momentary_fatigue_and_persistence_in_effort-based_choice?_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InByb2ZpbGUiLCJwYWdlIjoicHJvZmlsZSJ9fQ)
, Nature July 2021 12(1):4593

5.     Data Bridge Market Research:
https://www.databridgemarketresearch.com/reports/global-narcolepsy-treatment-market
(https://www.databridgemarketresearch.com/reports/global-narcolepsy-treatment-market)

 

Enquiries

 TheraCryf plc                                       +44 (0)1625 315 090

 Dr Huw Jones, CEO                                   enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, COO

 Singer Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7496 3000
 Phil Davies / Oliver Platts / Patrick Weaver

 Turner Pope Investments (Joint Broker)              +44 (0)20 3657 0050

 Guy McDougall / Andy Thacker

 Vigo Consulting                                     +44 (0)20 7390 0230

 Rozi Morris/ Melanie Toyne Sewell                   theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma*
and neurodevelopmental disorders [*orphan indication].

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know-how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the
ticker symbol TCF. 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFWFAWEISEIE



            Copyright 2019 Regulatory News Service, all rights reserved